AMP-activated protein kinase alpha 1 (AMPKα1)

AMP-activated protein kinase alpha 1 (AMPKα1) is the catalytic alpha subunit encoded by the PRKAA1 gene and one of two alpha isoforms that form the catalytic core of AMP-activated protein kinase (AMPK), a heterotrimeric serine/threonine kinase composed of a catalytic alpha subunit together with regulatory beta and gamma subunits. The gamma subunit binds adenine nucleotides, so that a rising AMP:ATP ratio promotes phosphorylation of a conserved threonine in the alpha subunit activation loop by upstream kinases including LKB1 and CaMKK2. AMPKα1 thereby serves as the enzymatic output of the cell's principal energy sensor: when adenosine triphosphate levels fall, it phosphorylates substrates that switch on catabolic, ATP-generating processes such as fatty acid oxidation, glucose uptake, and mitochondrial biogenesis, while restraining ATP-consuming anabolic pathways including fatty acid and cholesterol synthesis via targets such as acetyl-CoA carboxylase and, indirectly, fatty acid synthase (FASN).

Downstream of activation, AMPKα1 inhibits mechanistic target of rapamycin (Mtor) signaling and directly phosphorylates ULK1, coupling energy stress to induction of autophagy and mitophagy; it also intersects with Sirtuin 1 (Sirt1), PGC-1α–dependent mitochondrial biogenesis, Nrf2-mediated antioxidant defense, and the Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/mTOR axis that positions it opposite growth and proliferative signaling. These connections make AMPKα1 a recurring node in conditions defined by metabolic and oxidative stress, including type 2 diabetes and its complications such as diabetic neuropathy and nephropathy, obesity and impaired adipocyte catabolism, metabolic dysfunction–associated steatotic liver disease, cardiovascular disease encompassing myocardial fibrosis and heart failure with preserved ejection fraction, neurodegenerative disease such as Alzheimer's disease and Parkinson's disease, inflammation, aging, and cancer. Pharmacologically, AMPKα1 is the proximal effector of the biguanide metformin, whose actions on hepatic glucose output, and more speculatively on nociception and neuroprotection, are attributed largely to AMPK activation with downstream Mtor and MAPK suppression. It is likewise the convergence point for a broad set of natural products under investigation as metabolic modulators, including resveratrol, berberine, quercetin, kaempferol, urolithin A, and other polyphenols and flavonoids, as well as for pathway-directed agents such as the Mtor inhibitor sirolimus, and for signaling crosstalk with TGF-β, JAK2/STAT3, and PD-1/PD-L1 pathways in fibrotic and tumor settings.